Dr. Grey AI

Ganirelix (Antagon/Orgalutran)

Peptide

Ganirelix is a synthetic decapeptide GnRH antagonist. First FDA-approved GnRH antagonist in US (1999). Phase III trials show effective LH surge prevention with 0.25mg daily dose. Comparable pregnancy rates to GnRH agonist protocols (31.0% vs 33.9%). 2.4% OHSS rate vs 5.9% with agonists. Shorter treatment duration (5 vs 26 days) and fewer injections.

Quick Answer

What it is

Ganirelix is a synthetic decapeptide GnRH antagonist. First FDA-approved GnRH antagonist in US (1999).

Key findings

  • Grade A: LH Surge Prevention (Infertility)
  • Grade A: Pregnancy Rate (Infertility)
  • Grade A: OHSS Prevention (Infertility)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Ganirelix (Antagon/Orgalutran)

Quick Facts: Ganirelix (Antagon/Orgalutran)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:7
  • Grade A Findings:4
  • Grade B Findings:1
  • Key Effect:Infertility
A4
B1
C2
D0
1 conditions · 7 outcomes

Detailed Outcomes

A
LH Surge Prevention
Phase III: 0.25mg is minimal effective dose for LH surge prevention. Comparable efficacy to leuprolide and triptorelin protocols.
large↓Improves
A
Pregnancy Rate
Ongoing pregnancy rate 31.0% (ganirelix) vs 33.9% (triptorelin). Implantation rate identical at 22.9%. Comparable to GnRH agonist protocols.
moderate↑Improves
A
OHSS Prevention
2.4% OHSS incidence vs 5.9% with buserelin. Preferred protocol for high responders and oocyte donors.
moderate↓Worsens
A
Treatment Duration
5 days treatment vs 26 days with buserelin. Fewer injections required. Enhanced patient convenience and compliance.
large↓Improves
B
Reproductive Outcomes
18 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Safety/Tolerability
6 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Hair Growth
3 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (29)

Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).
(2025)
PMID: 40264185
Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study.
(2025)
PMID: 40297130
Real-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study.
(2025)
PMID: 41142490
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.
(2024)
PMID: 39861098
What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.
(2023)
PMID: 36594696
Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study
(2022)
PMID: 35254199
Correlation of LH level and steroid concentrations in GnRH antagonist protocol: A sub-analysis of Ganirelix phase III study of China
(2022)
PMID: 35318120
A Prospective Randomised Comparative Clinical Trial Study of Luteal PhaseLetrozole versus Ganirelix Acetate Administration to Prevent Severity of Early Onset OHSS in ARTs.
(2021)
PMID: 34913294
The effect of a GnRH antagonist on follicle maturation in normal women.
(2019)
PMID: 31129014
Evidence that the main adverse effect of ganirelix on pregnancy and implantation rates is on the embryo rather than the endometrium.
(2011)
PMID: 22268265